Pipeline of 5T4-Targeted Immunotherapies

La Merie Publishing has launched a new series of reports about the pipeline of targeted immunotherapies which are prepared on demand upon order placement. This enables an up to date evaluation of competitor projects. These reports are prepared within one working day upon order placement. The reports list the targeted R&D programs by R&D phase in a tabular format and describe in brief the profile of targeted immunotherapies by drug modality. The reports are provided in pdf format and sent by e-mail to the customer.

To showcase how such on demand reports about pipelines of targeted immunotherapies look like, La Merie Publishing offers the report Pipeline of 5T4-Targeted Immunotherapies released on August 18 2025 as a free sample for download: https://lamerie.com/wp-content/uploads/2025/08/Sample-of-5T4-Pipeline-Aug-18-2025.pdf

Cell-surface protein Trophoblast glycoprotein (TPBG) 5T4 is a highly expressed oncofetal tumor-associated antigen associated with adverse clinical outcomes in solid tumors, and is an attractive therapeutic target due to low expression on normal adult tissues, with most human expression being observed in utero. Analysis in fresh frozen healthy human tissue with the therapeutic mAb candidate of TUB-030 revealed limited cross reactivity. 5T4 is a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC). 5T4 on tumor cell surface is rapidly internalized when bound to antibody and is thus an ideal target for the development of ADC drugs. However, the slow internalization rate and low surface density have limited 5T4 as a tumor associated antigen for ADC drug development so far, but leaving opportunities for more efficient ADC technologies.